Basilea Pharmaceutica - Zevtera path to US approval open
On 28 June 2022, Basilea announced positive top-line results from the Phase III ERADICATE study, investigating the use of its drug-resistant...
672 Views
Basilea Pharmaceutica - Anti-infective refocusing on schedule
Management has provided an update on Basilea’s strategy to refocus the business on anti-infectives, as part of which, the company will cease all...
669 Views
Basilea Pharmaceutica - Cresemba IV formulation approved in China
Basilea has announced the approval in China of the intravenous (IV) formulation of Cresemba, the company’s antifungal drug, for treating adult...
676 Views
Basilea Pharmaceutica - Yet another milestone payment from Pfizer
Sales of Basilea’s antifungal drug, Cresemba (isavuconazole), in the Asia Pacific region have triggered a milestone payment of $1.25m from the...
667 Views
Basilea Pharmaceutica - Renewed focus on anti-infectives
In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology...
12 Views